| Simpson-Yap, S and De Brouwer, E and Kalincik, T and Rijke, N and Hillert, JA and Walton, C and Edan, G and Moreau, Y and Spelman, T and Geys, L and Parciak, T and Gautrais, C and Lazovski, N and Pirmani, A and Ardeshirdavanai, A and Forsberg, L and Glaser, A and McBurney, R and Schmidt, H and Bergmann, AB and Braune, S and Stahmann, A and Middleton, R and Salter, A and Fox, RJ and Van Der Walt, A and Butzkueven, H and Alroughani, R and Ozakbas, S and Rojas, JI and van der Mei, IAF and Nag, N and Ivanov, R and Sciascia Do Olival, G and Dias, AE and Magyari, M and Brum, D and Mendes, MF and Alonso, RN and Nicholas, RS and Bauer, J and Chertcoff, AS and Zabalza, A and Arrambide, G and Fidao, A and Comi, G and Peeters, L, “Associations of disease modifying therapies with COVID-19 severity in Multiple Sclerosis”, Neurology, 97 (19) pp. E1870-E1885. ISSN 0028-3878 (2021) [Refereed Article] |
